CYTK — Cytokinetics Income Statement
0.000.00%
Last trade - 00:00- $4.82bn
- $4.40bn
- $18.47m
Annual income statement for Cytokinetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.8 | 70.4 | 94.6 | 7.53 | 18.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 150 | 257 | 444 | 504 | 555 |
| Operating Profit | -93.9 | -186 | -349 | -496 | -536 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -127 | -215 | -389 | -526 | -590 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -127 | -215 | -389 | -526 | -590 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -127 | -215 | -389 | -526 | -590 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -127 | -215 | -389 | -526 | -590 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.97 | -2.76 | -4.05 | -5.45 | -5.26 |